Get the Stockscreener App
5.89
0.86%
+0.05
After Hours:
5.8998
0.0098
+0.17%
CorMedix Inc stock is currently priced at $5.89, with a 24-hour trading volume of 747.53K.
It has seen a +0.86% increased in the last 24 hours and a +25.05% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.73 pivot point. If it approaches the $6.03 resistance level, significant changes may occur.
Previous Close:
$5.84
Open:
$5.95
24h Volume:
747.53K
Market Cap:
$323.84M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-6.8488
EPS:
-0.86
Net Cash Flow:
$-38.74M
1W Performance:
+11.55%
1M Performance:
+25.05%
6M Performance:
+70.72%
1Y Performance:
+18.99%
1D Range:
$5.83
$6.075
52W Range:
$2.57
$7.00
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
Zacks Investment Research
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
GlobeNewswire Inc.
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
GlobeNewswire Inc.
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
Zacks Investment Research
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
GlobeNewswire Inc.
CorMedix (CRMD) Q4 2023 Earnings Call Transcript
The Motley Fool
CorMedix Inc Stock (CRMD) Financials Data
CorMedix Inc (CRMD) Revenue 2024
CRMD reported a revenue (TTM) of $65.40 thousand for the quarter ending December 31, 2022, a -65.74% decline year-over-year.
CorMedix Inc (CRMD) Net Income 2024
CRMD net income (TTM) was -$46.34 million for the quarter ending December 31, 2023, a -56.02% decrease year-over-year.
CorMedix Inc (CRMD) Cash Flow 2024
CRMD recorded a free cash flow (TTM) of -$38.74 million for the quarter ending December 31, 2023, a -57.62% decrease year-over-year.
CorMedix Inc (CRMD) Earnings per Share 2024
CRMD earnings per share (TTM) was -$0.92 for the quarter ending December 31, 2023, a -24.32% decline year-over-year.
CorMedix Inc Stock (CRMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Todisco Joseph | Chief Executive Officer |
Mar 13 '24 |
Buy |
3.74 |
13,561 |
50,718 |
352,839 |
| DUNTON ALAN W | Director |
Dec 15 '23 |
Buy |
3.30 |
3,000 |
9,900 |
15,250 |
| DUNTON ALAN W | Director |
Dec 14 '23 |
Buy |
3.45 |
3,000 |
10,350 |
12,250 |
| Mistry Erin | Chief Commercial Officer |
Nov 17 '23 |
Buy |
4.00 |
1,000 |
4,000 |
4,900 |
| Lefkowitz Steven W | Director |
Nov 16 '23 |
Option Exercise |
2.25 |
15,000 |
33,750 |
75,498 |
| Todisco Joseph | Chief Executive Officer |
Sep 08 '23 |
Buy |
3.71 |
10,000 |
37,100 |
219,726 |
| Kaplan Myron | Director |
May 18 '23 |
Buy |
4.54 |
6,000 |
27,258 |
166,034 |
About CorMedix Inc
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
0.41%
0.14%
Cap:
|
Volume (24h):